PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26222F0045Isotope NUKE medicine ra-223 dichloride — Bayer Healthcare Pharmaceuticals Inc

Bayer Healthcare Pharmaceuticals Inc holds $14.3M across 87 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent 36F79720D0237. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Mar 30, 2023 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

262-Network Contract Office 22 (36C262)

Awarding office

Bayer Healthcare Pharmaceuticals Inc

Recipient

Mar 30, 2023

PoP end

$274K

Obligated

$254K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Bayer Healthcare Pharmaceuticals Inc — $90

Contract facts

Federal

Contract number36C26222F0045

Also listed as36C262-22-F-0045

Also listed as36F79720D0237-36C26222F0045

Agency262-Network Contract Office 22 (36C262)

Awarding office262-Network Contract Office 22 (36C262)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentBayer Healthcare Pharmaceuticals Inc

CAGE59463

UEIV1EVGCK7XES8

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79720D0237

Place of performanceDUBLIN OH

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startOct 15, 2021

PoP end (current)Mar 30, 2023

PoP end (w/ options)Sep 30, 2023

Obligated$274K

Current value$274K

Potential value$254K

ISOTOPE NUKE MEDICINE RA-223 DICHLORIDE is a federal award for 262-Network Contract Office 22 (36C262) held by Bayer Healthcare Pharmaceuticals Inc. Estimated value $254K ($274K obligated). Current period of performance ends Mar 30, 2023 (potential Sep 30, 2023). Last award drew 1 bidder. Place of performance: DUBLIN OH.

Recompete timing

Public

● Past PoP end (1240 days ago)

Current PoP ended Mar 30, 2023 (1240 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Bayer Healthcare Pharmaceuticals Inc — $14.3M obligated across 87 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($14.3M) · all agencies

Department of Health and Human Services (HHS)$15.1M · 106%Department of Defense (DOD)$387K · 3%Department of Justice (DOJ)$345K · 2%

Open full company profile →

Related awards

Same parent · incumbent

75A50325F80035

PURCHASE CIPROFLOXACIN 250MG/5ML ORAL SUSPENSION, POWDER, 100ML BOTTLE

$15.1M

Sep 29, 2026

36C26226F0163

XOFIGO - RADIUM RA 223DICHLORIDE INJ

$181K

Mar 31, 2027

SPE2D026F0101

8511938413!OTHER MEDICAL

$120K

Apr 5, 2027

36C25626N0492

XOFIGO RADIUM 223 FOR CANCER TREATMENT.

$387K

Apr 9, 2027

36C24723F0573

RA-223 DICHLORIDE XOFIGO RADIO PHARM

$264K

Jun 30, 2028

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26222F0045?

36C26222F0045 (Isotope NUKE medicine ra-223 dichloride) is a 262-Network Contract Office 22 (36C262) award with a potential value of $254K, currently held by Bayer Healthcare Pharmaceuticals Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C262-22-F-0045?

36C262-22-F-0045 is the dashed form of PIID 36C26222F0045 (Isotope NUKE medicine ra-223 dichloride), held by Bayer Healthcare Pharmaceuticals Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26222F0045?

262-Network Contract Office 22 (36C262) awarded 36C26222F0045 to Bayer Healthcare Pharmaceuticals Inc (potential $254K).

Who is the incumbent on 36C26222F0045?

Bayer Healthcare Pharmaceuticals Inc is the incumbent with $14.3M across 87 related awards in SCOUT’s public footprint. The current period of performance ends Mar 30, 2023.

When does Bayer Healthcare Pharmaceuticals Inc’s 36C26222F0045 come up for recompete?

SCOUT tracks a period-of-performance end of Mar 30, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jul 2, 2026 · refreshed monthlyLatest procurement action Mar 30, 2023